ARRANON
Total Payments
$108,451
Transactions
4
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $14,562 | 1 | 0 |
| 2017 | $93,889 | 3 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $108,451 | 4 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHARMACOKINETIC AND PHARMACODYNAMIC STUDY TO EVALUATE THE SAFETY AND FEASIBILITY OF CONTINUOUS INFUSION NELARABINE IN PATIENTS WITH RELAPSED REFRACTORY LYMPHOID MALIGNANCIES | Novartis Pharmaceuticals Corporation | $71,160 | 0 |
| A PHASE I TRIAL OF NECTAR NELARBINE ETOPOSIDE AND CYCLOPHOSPHAMIDE IN T ALL RELAPSE A JOINT STUDY OF TALC AND POETIC | Novartis Pharmaceuticals Corporation | $30,365 | 0 |
| A Phase IV Trial of NECTAR Nelarbine, Etoposide and Cyclophosphamide in T ALL Relapse A Joint Study of TALC and POETIC | Novartis Pharmaceuticals Corporation | $6,926 | 0 |
Top Doctors Receiving Payments for ARRANON
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Houston, TX | $108,451 | 4 |
Ad
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $108,451
Product Information
- Type Drug
- Total Payments $108,451
- Total Doctors 0
- Transactions 4
About ARRANON
ARRANON is a drug associated with $108,451 in payments to 0 healthcare providers, recorded across 4 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2018. In 2018, $14,562 was paid across 1 transactions to 0 doctors.
The most common payment nature for ARRANON is "Unspecified" ($108,451, 100.0% of total).
ARRANON is associated with 3 research studies, including "A PHARMACOKINETIC AND PHARMACODYNAMIC STUDY TO EVALUATE THE SAFETY AND FEASIBILITY OF CONTINUOUS INFUSION NELARABINE IN PATIENTS WITH RELAPSED REFRACTORY LYMPHOID MALIGNANCIES" ($71,160).